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Objectives: To estimate the calcium levels in peri menopausal and postmeno-
pausal women and to evaluate the need for calcium supplementation among 
them. MethOds: A prospective study was conducted at gynecology department of 
a tertiary care hospital for the period of six months to estimate the serum calcium 
levels among them. Study populations were divided in to perimenopausal and post 
menopausal group. All the eligible patients were enrolled after obtaining informed 
consent. Study subjects from both the group were estimated for serum calcium 
levels to identify if they need calcium supplements. Unpaired T test was performed 
to find out any significant difference between both groups and pearson’s corre-
lation cofficient (r) was applied to assess the relation between age and calcium 
levels. Results: During the study period, 53 of 100 patients enrolled were postmen-
opausal with the mean age of 60.8±10.47 years and 47 of 100 patients enrolled were 
perimenopausal with mean age of 44.6±3.54 years. The mean calcium level of 47 
perimenopausal women was found to be 9.32±0.55 (reference level: 8.0-11.0 mg/dl) 
and 8.56±0.54 for 53 postmenopausal women. In post menopausal women there 
was highly significant drop observed in serum calcium levels with increasing age, 
compared to peri menopausal women. (CI: 95%, p< 0.0001, r: -0.81). cOnclusiOns: 
The serum concentrations of calcium in majority of our study population were 
within the normal range. There was a good source of dietary intake of calcium in 
most of the patients. The levels of calcium were lower in postmenopausal women 
compared to perimenopausal women. Since there is an negative effect of calcium 
on the bone mineral density in postmenopausal women, it can be recommended 
that calcium supplementation can be given as prophylaxis to prevent the long 
term bone loss and to decrease the risk of fracture and osteoporosis.
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Objectives: Describe patient characteristics and medication treatment 
patterns among newly diagnosed cases of BPH-LUTS, ED, and co-occurring ED 
and BPH-LUTS. MethOds: Retrospective cohort study using UK CPRD data on 
incident BPH-LUTS and incident ED patients indexed between June 2010 and 
May 2011. Patient records were analysed from 12 months pre-index and up to 
24 months post-index. Results: The cohort included 8912 men with BPH-LUTS-only, 
2589 with an ED diagnosis followed by BPH-LUTS, 8093 with ED-only and 1641 
with a BPH-LUTS diagnosis followed by ED, all aged ≥ 40 years. The majority of 
BPH-LUTS patients (~90%) were diagnosed and managed within GP practices. 
Men were diagnosed with BPH-LUTS alone at an older average age (68±11.9 years, 
IQR= 59–77) compared to men in the ED/BPH-LUTS group (67±9.5 years, IQR= 61–74, 
p= 0.002). Men were diagnosed with ED at an older average age (65±9.2 years, 
IQR= 59–72) in the BPH-LUTS/ED group compared with ED-only patients (57±9.1 
years, IQR= 50–64, p< 0.001). Time between diagnoses was longer for ED/BPH-LUTS 
patients (6.8±4.76 years) versus BPH-LUTS/ED patients (5.8±5.10 years). BPH-LUTS 
and ED treatment patterns were similar for patients with and without co-occurring 
conditions. Most patients were initially prescribed alpha-blockers (62.9% BPH-
only, 65.5% ED/BPH-LUTS) or anticholinergics (14.9% BPH-only, 14.0% ED/BPH-
LUTS). For ED, most patients were initially prescribed sildenafil (51.6% ED-only, 
49.6% BPH-LUTS/ED) or tadalafil (24.3% ED-only, 26.0% BPH-LUTS/ED). At six 
months post-diagnosis, ~47% incident BPH-LUTS patients and ~78% ED patients 
were not on any BPH-LUTS or ED treatment, respectively. cOnclusiOns: Study 
data suggests > 80% of patients are managed as either BPH-LUTS- or ED-only. 
Average age of BPH-LUTS/ED patients at ED diagnosis suggests patients may suf-
fer from ED years before seeking medical attention (p= 0.002). Presence of the 
co-occurring condition does not appear to impact treatment choice, however, 
a lower proportion of ED patients initiate treatment after diagnosis, compared 
with BPH-LUTS patients.
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Rebollo P.1, Arenas M.D.2, Castejón N.1, Reichert García J.2, Delgado Conde P.2,  
Gutierrez Rivas P.2, Gil González M.T.2
1LASER ANALYTICA, Oviedo, Spain, 2Hospital Vithas Perpetuo Socorro, Alicante, Spain
Objectives: To analyse the incidence of pain and the need of analgesics dur-
ing haemodialysis sessions, and its impact on Health-Related Quality of Life 
(HRQoL). MethOds: Data about the number of sessions in which 172 patients 
showed pain and needed analgesics were collected in 2 haemodialysis units in Spain 
during 3 months. Age, sex, comorbidities, (diabetes and cancer history), time on 
haemodialysis, pain complaints during haemodialysis sessions, intake of analgesics, 
opioids and antidepressant drugs, were collected. Generic HRQoL was assessed by 
means of the computer adaptive test CAT-Health, previously validated, through an 
iPAD. A negative score means that the HRQoL is worse than that of general popula-
tion and a positive score, indicates that it is better. Results: Mean age (S. D) was 
66.87 (13.32), being 44 patients (25.6%) aged over 75 years. 55.8% were male, 34.3% 
diabetic and 11.6% had cancer history. The median time undergoing haemodialysis 
was 51.50 months (27.75-84.50). 81 patients (47.4%) had pain during some session. 
The mean number of haemodialysis sessions with pain was 4.78 (range between 
1 and 21 sessions), which represents 12.7% of the total number of sessions. 67 
patients (39%) were usually taking analgesics, 37 (21.5%) opioids and 29 (16.9%) 
antidepressant drugs. Patients taking analgesics showed worse HRQoL: mean (S. 
Objectives: The current study looks to explore young children from high-risk fami-
lies in the Taipei City setting. High-risk social welfare intervention was investigated. 
First, differences between enrollees and non-enrollees for medical subsidy program 
among high-risk family whose cases were started in 2009 or 2010 will be looked at. 
Second, the study will try to determine the social welfare intervention’s effective-
ness in increasing application for medical subsidy program and finding any predic-
tors which may have helped or harmed application for enrollment. MethOds: The 
study sample included under 6 year old children high-risk families (n= 199). High-
risk family database and medical subsidy database were linked. Differences between 
high-risk subsidy enrollees (n= 87) and non-enrollees (n= 112) and effectiveness of a 
social welfare intervention in increasing subsidy application were investigated in a 
pre-post analysis of high-risk social welfare intervention. Individual level as well as 
relative residential level characteristics were explored. Results: Medical subsidy 
enrollment was correlated with younger age at time of a high-risk intervention and 
relative district level variables. Pre-post comparison suggests high-risk interventions 
significantly increased subsidy application by 7.4%. Logistic regression indicates 
older age at time of intervention was associated with 40% less chance of applica-
tion. cOnclusiOns: The study provides empirical evidence for potential effects of a 
high risk social welfare intervention on the accessibility to health care. Findings also 
show where policy makers can improve intervention in order to address the needs 
children at-risk, especially for different age groups.
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Objectives: When the WHO launched the Expanded Programme on Immunisation 
(EPI) in 1974, < 5% of the world’s children were vaccinated against polio, measles, 
diphtheria, tetanus, pertussis and tuberculosis. Nowadays coverage rates are 
increasing and more vaccines have been added to the programme. This project 
aims to identify factors associated with successful programmes based on EPI cov-
erage. MethOds: The relationship between multiple socio-demographic and eco-
nomic factors and EPI coverage (primarily obtained from the WHO and World Bank) 
was investigated using simple linear regression, Principal Component Analysis (PCA) 
to identify explanatory variables, and finally multiple linear regression analysis. 132 
countries with data on self-funded health care programmes were included in the 
analysis. These were ranked according to Gross National Income (GNI) per capita and 
lower (L), lower-middle (LM), upper-middle (UM) and upper (U) quartiles were identi-
fied. Results: Income (GNI/capita) was not significantly associated with achiev-
ing high EPI coverage rates. Within the income groups the factors trending with 
improved EPI coverage included: 5-yr mortality and corruption index in L, sanitary 
facilities in LM, 5-yr mortality, sanitary facilities, birth-rate and life-expectancy in 
UM. In U all countries achieved > 90% coverage. cOnclusiOns: Identifying simple 
predictive variables of successful vaccination programmes is complex because of 
multicollinearity. However, by exploring within homogeneous income groups, it was 
possible to identify underlying factors related to vaccination programme success. As 
the core EPI vaccines were introduced 40yrs ago one would expect introduction to 
have been fully implemented thus reducing the likelihood of a relationship between 
country income and coverage today, however it could have been expected some time 
ago. To further explore the relationship between country income and vaccination 
programme success, one could expand the analysis to include the newer vaccines 
as soon as coverage information is available for a majority of the countries.
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Objectives: Despite existing examples of the great impact successful integration 
of PRO science and know-how may have on improving market access, PROs are typi-
cally not part of drug development decision making such as go/no-go decisions. The 
objective of this study is to identify decision making instances in drug development 
when important go/no-go decision making also could have included PROs but typically 
weren’t. Additionally, search for any strategies and activities that might better enhance 
the likelihood for senior decision makers also to integrate PRO science and knowhow 
in drug development decision making. MethOds: A literature search was carried 
out including terms such as PRO, strategy, decision-making, go/no-go decisions, drug 
development and phases I to IV. Results: Typical go/no-go decisions mentioned in the 
literature include decisions to move a drug candidate from one development phase to 
the next stage, i. e. from target-to hit to launch decisions. There were very few references 
found where go/no-go decision-making in drug development also included PROs. Many 
references also states the necessity to include the patient (e. g. listen to the patient) early 
on in drug development. However, no concrete suggestions on how to carry out these 
ambitions in practice were found. cOnclusiOns: There is little research to be found in 
the literature on go/no-go decision making in drug development where PRO science and 
knowhow are taken into account. The lack of clear practical guidance and examples on 
when and how to start inclusion of PROs science and knowhow in go/no-go 
decision making may be one impediment to their successful inclusion. Perhaps, a best 
practice rule could be as simple as including a PRO opportunity assessment in phase 
I-II go/no-go decisions where the feasibility, pros and cons for potentially including 
PRO in the clinical development program are summarized. At least, a first overview 
of PROs potential is done.
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pleted Patient Record Forms (PRFs); pts self-reported data including EQ-5D and the 
Work Productivity and Activity Impairment Index for SLE (WPAI-Lupus) in Patient 
Self-Completion Records (PSCs). Pt eligibility was determined by physicians; disease 
activity and severity were based on physician assessment. Data across countries 
were pooled. Results: Data were collected from rheumatologists in the USA (n= 97), 
France (n= 37) and Germany (n= 35), including PRFs (550/200/207, respectively) and 
PSCs (303/109/149, respectively). Physician assessment of disease severity was pre-
dominantly based on affected organs and symptoms (45% and 35% of rheumatolo-
gists, respectively); 15% based severity on test results/clinical assessments. No disease 
activity index was widely used, 58% used their own assessment. Physician assessment 
of severity was imperfectly correlated with control of disease activity (activity con-
trolled in 56.1% of “moderate-to-severe” pts, uncontrolled in 6.1% of “mild” pts). Pts 
with “moderate-to-severe” severity presented with greater severity and organ involve-
ment, and a higher proportion experienced flares per 12-month period than “mild” 
pts (78.4% vs 52.6%). “Moderate-to-severe” severity was associated with a greater 
impact on HRQoL (EQ-5D: 0.72 vs 0.86; WPAI: 35.0 vs 16.3) than “mild” disease. Fewer 
“moderate-to-severe” pts were employed (full-time employment: 35.8% vs 48.8%), 
and a higher proportion required a care provider (6.6% vs 3.3%). cOnclusiOns: SLE 
severity is not consistently assessed or defined in clinical practice: measures used in 
clinical trials are not routinely adopted in daily practice, whilst organ involvement 
and symptoms are central to physician assessment of severity. Correlation between 
severity and control of disease activity is imperfect. “Moderate-to-severe” severity is 
associated with a greater burden than “mild” disease.
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effeCtIVeness of HeaVy-lIgHt CHaIn QuantItatIVe test:  
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Objectives: Heavy-light chain (HLC) quantitative test can identity and quan-
tify the heavy and light chain of each immunoglobulin class. The purpose of this 
study was to evaluate the effectiveness of HLC quantitative test. MethOds: To 
evaluate the effectiveness of HLC quantitative test, systemic literature review using 
Ovid-MEDLINE, EMBASE, Cochrane library and eight domestic databases including 
KoreaMED had performed until October 10th, 2013. We included five cohort studies 
and one diagnostic evaluation study in the final evaluation. Two reviewers inde-
pendently assessed the quality of included studies and extracted data on study. 
The qualities of these studies were assessed according to Scottish Intercollegiate 
Guidelines Network (SIGN) tool. Results: The correlation between HLC quanti-
tative test with previous tests was evaluated in one study which patients with 
increased monoclonal IgA were enrolled, and the correlation coefficient with com-
parator tests was reported as 0.94 in that study. Clinical significance of quantitative 
HLC test for predicting prognosis was also reported in five cohort studies. Survival 
rate in patients with higher HLC ratio was significantly lower, and the increased 
IgA κ /λ ratio or IgM κ /λ ratio was significantly correlated with higher survival rate 
in patients with monoclonal gammaglobulinemia. The body of evidence as a whole 
suggests a Grade C for HLC quantitative test. cOnclusiOns: HLC quantitative test 
is safe and effective test that can quantitatively measure the identified immuno-
globulin type and predict the prognosis of patients with monoclonal gammopathy.
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Objectives: The CLL11 study (stage 2, NCT02053610; sponsored by F. Hoffmann-La 
Roche, Basel, Switzerland), compared G-Clb with R-Clb in 663 patients with previ-
ously untreated CLL and comorbidities. We compared the presence, disappearance 
and duration of absence of B-symptoms (fever, night sweats and weight loss) for 
G-Clb with R-Clb in CLL11. MethOds: Patients were randomised to receive six 
28-day (D) cycles (C) of G-Clb (N= 333) or R-Clb (N= 330; G: 1000 mg D1, 8 and 15 C1, 
D1C2–6; R: 375 mg/m2 D1C1, 500 mg/m2 D1C2–6; Clb: 0.5 mg/kg D1 and 15 each 
cycle). B-symptoms were assessed by a physician at baseline, D1C1, D8C1, D1 of 
each subsequent cycle, 28 days after last study drug and every 3–6 months dur-
ing follow-up for progression-free survival. The data cut-off for this analysis was 
9thMay 2013. Results: At baseline, 260 patients had B-symptoms (n= 126, G-Clb; 
n= 134, R-Clb). During the treatment period, B-symptoms disappeared in 107 (85%) 
and 124 (93%) patients who received G-Clb and R-Clb, respectively (relative risk 
[RR]: 0.92, 95% confidence interval [CI]: 0.84–1.00; p= 0.0554). Median time to first 
disappearance of all B-symptoms was 32.0 days for G-Clb and 35.0 days for R-Clb 
(hazard ratio [HR]: 1.24,95% CI: 0.96–1.61; p= 0.103). At end of treatment, 96 (76%) 
and 108 (81%) patients who received G-Clb and R-Clb, respectively, were B-symptom 
free (RR: 0.95, 95% CI: 0.83–1.07; p= 0.3899). In patients whose B-symptoms disap-
peared, the 25% quartile for duration of absence of B-symptoms (median not 
reached) was 16.4 months for G-Clb and 10.4 months for R-Clb (HR: 0.59, 95% CI: 
0.36–0.97; p= 0.0387). cOnclusiOns: There was no clinically meaningful difference 
in B-symptom freeness at end of treatment, however the absence of B-symptoms 
was prolonged by 6 months for G-Clb versus R-Clb.
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Objectives: To compare the disease status and outcomes of patients with AS 
receiving adalimumab and etanercept monotherapy in Europe. MethOds: A multi-
D) CAT-Health scores of -1.2412 (1.6065) vs -0.0119 (1.3495) (p< 0.001). Patients tak-
ing opioids also showed worse scores: -1.1009 (1.9349) vs -0.3288 (1.4169) (p= 0.037). 
Differences on HRQoL according to antidepressant drugs were not statistically sig-
nificant. Episodes of pain during dialysis were concentrated in 24 patients who had 
6 or more painful sessions. These patients were taking analgesics more frequently 
(86.4% vs 36.9%; p< 0.001) and showed worse CAT-Health score: -1.5391 (1.6348) vs 
-0.3243 (1.4981) (p= 0.005). cOnclusiOns: Pain during haemodialysis sessions is 
very common and requires the frequent use of analgesics, having a negative impact 
on patients’ HRQoL.
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Objectives: COLLECT scale assesses comorbidities in patients with Chronic 
Lymphocytic Leukemia (CLL). Validation of COLLECT was a secondary objective 
of the MABERYC non-interventional study. The aim is to assess the clinical util-
ity and the validity of COLLECT to guide treatment regimen prescribed to CLL 
patients. MethOds: MABERYC study included patients with CLL, being or not previ-
ously treated, initiating treatment with Rituximab+chemotherapy. COLLECT was 
administered at baseline and 12 months following treatment finalization. Treatment 
response (TR) and safety was also assessed in the last visit. COLLECT categorizes 
comorbidity in low (0-3), moderate (4-7) and high (> 7). Changes in COLLECT were 
categorized in improvement (reduction≥ 2), without changes (variation< 2) and 
worsening (increase≥ 2). Results: MABERYC included 218 patients, 179 completed 
COLLECT at baseline. Patients had a mean age of 67.5 years, 73% were male, 53% 
were naïve, 37% had moderate comorbidity and 27% high comorbidity. At baseline, 
42% of patients initiated treatment with Rituximab-Fludarabine-Ciclofosfamide 
(RFC), 30% with Rituximab-Bendamustine (RB), 18% with Rituximab-Clorambucile 
(RC) and 10% other patterns. Mean COLLECT score was higher in older patient, 
higher ECOG, previously treated (5.2 vs 4.2) and those receiving less aggressive treat-
ments (5.8 RC, 5.4 RB, 3.6 RFC). Changes in COLLECT were analysed in 134 patients. 
CR could be associated to improvement in comorbidity. Complete remission was 
reached by 53% of patients with COLLECT improvement, 47% without changes, and 
32% worsening. Number of adverse events (AEs) treatment related tend to be higher 
in patient with lower comorbidity (1.6 vs 0.9), using more aggressive treatments. 
Total number of AEs (related or not to treatment) tend to be higher in patients with 
higher comorbidity (7.8 vs 5.8). cOnclusiOns: COLLECT scale assess comorbid-
ity which is related with patients’ profile, treatment regiment prescribed, CR and 
AEs. COLLECT could assist decision-making on the intensity of the chemotherapy 
regimen to prescribe.
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1University of Montreal, Montreal, QC, Canada, 2AbbVie Canada, Saint-Laurent, QC, Canada, 
3AbbVie Canada, St-Laurent, QC, Canada
Objectives: Psoriasis is a chronic inflammatory disease of the skin that cannot 
be cured. For patients with active moderate to severe psoriasis, biologics use is 
associated with an improvement in patients’ quality of life especially by reducing 
prevalence of psychological disorders. The objective of this study was to assess 
the impact of biologics use on depression and anxiety frequency and the number 
of medical visits. MethOds: A retrospective study of the Quebec provincial drug 
reimbursement program (RAMQ) database was conducted using a randomly selected 
group of patients who have received at least one diagnosis of psoriasis between 
January 1st, 2007 and June 30th, 2012. To assess the impact of biologics use, time series 
analyses were performed. Time series analyses evaluate changes in the slope of a 
trend pre- and post-intervention, herein defined as biologics initiation. Trends in 
depression and anxiety frequency and medical visits frequency were compared for 
each year for a 5-year period before and after biologics initiation to assess the dif-
ferences in slopes. Results: A total of 43,400 patients with psoriasis were included 
in the study (mean age= 54.6 [SD= 21.9] years, 53.7% females), of which 1,108 (2.6%) 
used a biologic agent. For patients who needed to be treated with biologics, the 
rates of change in the depression and anxiety prevalence increased by 3.4% and by 
4.2% per year prior to biologics initiation respectively. After biologics initiation, the 
trends were still increasing, but at a statistically lower rate of 2.5% (p= 0.028) and of 
2.4% (p= 0.012) per year. Medical visits per patient increased during the 5-year period 
before biologics initiation. Visits frequency has reduced during the 5-year period 
after biologics initiation with a trend decreasing annually (p= 0.002). cOnclusiOns: 
The present analysis illustrates that biologics use reduces the increase in depression 
and anxiety frequency and decreases the number of medical visits.
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a real-World CHaraCterIzatIon of PatIents WItH “Moderate-to-
seVere” systeMIC luPus erytHeMatosus
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Objectives: To characterize the patient (pt) group classified by physicians as hav-
ing “moderate-to-severe” systemic lupus erythematosus (SLE) disease severity, and 
assess disease burden. MethOds: Data were extracted from the Adelphi 2013 Lupus 
Disease-Specific Program, a multinational survey of clinical practice. Physicians com-
